195 related articles for article (PubMed ID: 21997171)
1. The impact of body weight on ovarian cancer outcomes.
Backes FJ; Nagel CI; Bussewitz E; Donner J; Hade E; Salani R
Int J Gynecol Cancer; 2011 Dec; 21(9):1601-5. PubMed ID: 21997171
[TBL] [Abstract][Full Text] [Related]
2. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
Mardas M; Stelmach-Mardas M; Madry R
Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
[TBL] [Abstract][Full Text] [Related]
3. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Tran AQ; Cohen JG; Li AJ
Gynecol Oncol; 2015 Aug; 138(2):263-6. PubMed ID: 26037901
[TBL] [Abstract][Full Text] [Related]
4. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
5. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
6. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
7. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
8. Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.
Levin G; Brezinov Y; Tzur Y; Bar-Noy T; Brodeur MN; Salvador S; Lau S; Gotlieb W
Arch Gynecol Obstet; 2024 Jul; 310(1):587-593. PubMed ID: 38714562
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
10. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
11. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Gynecol Oncol; 2018 Jan; 148(1):62-67. PubMed ID: 29174056
[TBL] [Abstract][Full Text] [Related]
12. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
13. Impact of underweight after treatment on prognosis of advanced-stage ovarian cancer.
Kim SI; Kim HS; Kim TH; Suh DH; Kim K; No JH; Chung HH; Kim YB; Song YS
J Immunol Res; 2014; 2014():349546. PubMed ID: 25050383
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity on surgical and oncologic outcomes in ovarian cancer.
Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2014 Oct; 135(1):19-24. PubMed ID: 25110330
[TBL] [Abstract][Full Text] [Related]
15. The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
Kong L; Li X; Xu Q; Wei L; Wang J; Cui H; Wang S; Zhao Y
Chemotherapy; 2011; 57(3):209-16. PubMed ID: 21555882
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
17. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
18. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Barrett SV; Paul J; Hay A; Vasey PA; Kaye SB; Glasspool RM;
Ann Oncol; 2008 May; 19(5):898-902. PubMed ID: 18272913
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
20. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]